JP5448248B2 - Food containing isoleucine in containers - Google Patents

Description

  The present invention relates to a container-containing isoleucine-containing food containing an isoleucine and containing a food in the form of powder, granules, plates, sticks, gels or liquids in a container.

(Background of the Invention)
Essential amino acids are essential nutritional elements to maintain human life and to make daily life comfortable, but because they have therapeutic effects on various diseases, etc., active ingredients such as pharmaceuticals, nutrients or supplements It is used as
For example, drugs for abnormal glucose tolerance and foods and drinks containing at least one of leucine, isoleucine and valine have been proposed (Patent Documents 1 and 2). In these publications, leucine alone or a mixture of leucine, isoleucine and valine is orally administered to rats in an amount of 1.5 g / Kg, and blood glucose level is actually used in the examples. We are looking at changes. This drug for abnormal glucose tolerance is said to be particularly effective for the treatment, improvement and / or prevention of abnormal glucose tolerance with liver damage, for which it is difficult to use conventional diabetes drugs.
There has also been proposed a pharmaceutical composition comprising a combination of at least one branched amino acid selected from leucine, isoleucine and valine and a drug such as a therapeutic drug for diabetes. And when it is orally administered to a rat, it is said that remarkable blood glucose fall is obtained by combined use (patent document 3).
However, there is a need for foods that can easily and easily improve blood sugar levels on a daily basis, even when there is anxiety about blood sugar levels, even for people who do not have liver damage.

JP 2003-171271 A JP 2006-28194 A WO2005-049006

An object of this invention is to provide the foodstuff in a container which can improve a blood glucose level on a daily basis simply.
The present invention is made based on the knowledge that the above-mentioned problems can be solved by containing a quantity of food that can be ingested in a container at a time and adding a specific quantity of isoleucine in a small quantity.
That is, the present invention provides a food containing isoleucine, which is a food in a container for taking at least 1 g of isoleucine in a single dose.

The mechanism of digestion and absorption varies depending on the type of food. In general, a glycemic index (GI) is used as a measure of the ease of an increase in blood glucose level after food intake, and the increase and increase patterns of blood glucose level after intake differ for each food even with the same energy intake. Furthermore, the blood sugar level also depends on the amount of meal, the amount of fiber, the amount of fat, and how it is cooked. In addition, differences in individual eating habits, such as meal time and the number of chews, also affect.
Foods can be classified as high GI foods, medium GI foods, and low GI foods. Compared with GI with glucose as 100, high GI foods include maltose GI of 105, rock sugar 100, fine white sugar 99, loaf bread 100, and French bread 95. To drop. Examples of the medium GI food include GI of cooked rice (milled rice) of 85, donut 86, porridge 57, castella 69, boiled potato 90, corn 75, banana 56, spaghetti 50, and pineapple 65. Examples of the low GI food include apple GI of 36, none 32, green soybean 30, agar 12, konjac 24, and tuna 40.
Thus, although a glycemic index changes with foodstuffs, in this invention, the blood glucose rise after ingestion of the above-mentioned middle GI meal represented by the main rice, more specifically, the foodstuff with GI of 50-90 can be suppressed. More preferably, it shows an excellent effect when the subject is ingested cooked rice with a high selection frequency in Japan. Furthermore, the increase in human blood sugar can be suppressed without side effects such as hypoglycemia.

As the isoleucine used in the present invention, any of L-form, D-form and DL-form can be used, but the L-form is preferably used.
Examples of the food containing isoleucine in the present invention include various forms of food such as powder, granules, plates, sticks, gels, and liquids. Liquid foods are preferable, and beverages are particularly preferable.
In the present invention, it is necessary to be accommodated in a container so that at least 1 g of isoleucine can be ingested in a single dose. That is, when all of the food contained in the container is ingested, at least 1 g of isoleucine is brought into the human stomach. Of these, foods that can take at least 2 g of isoleucine in a single dose are preferred. On the other hand, the maximum amount of isoleucine in a single dose is preferably 15 g or less.
When the food targeted in the present invention is a beverage, tea-based, coffee-based, sports-based or alcoholic beverages are preferred, and beverages in containers with a capacity of 500 ml or less, preferably 350 ml or less are particularly preferred. Among these, it is a beverage contained in a container having a capacity of 50 to 350 ml, particularly 100 to 350 ml, and preferably contains 3.5 to 10.5 g, preferably 3.5 to 7 g of isoleucine per 350 ml.

The food of the present invention can further contain leucine and / or valine. When leucine / or valine or a combination thereof is contained, the dose at one time is preferably 1 to 4 g.
Furthermore, indigestible dextrin which is one kind of water-soluble dietary fiber can be used in combination. When an indigestible dextrin is used in combination, advantages such as additively enhancing the effect of improving blood glucose level can be obtained without impairing the feeling of taking such as taste. Examples of commercially available indigestible dextrin include Fiber Sol 2 (manufactured by Matsutani Chemical Industry Co., Ltd.), Pine Fiber (manufactured by Matsutani Chemical Industry Co., Ltd.), and Nutriose (manufactured by Rocket Corporation). The dose of indigestible dextrin at one time is preferably 2 to 10 g. Indigestible dextrin is particularly preferably used in a coffee-based beverage in combination with isoleucine.
Various natural and synthetic sweeteners, colorants, fragrances, and the like can be further blended in the food targeted by the present invention.

It is preferable that the food targeted by the present invention contains as little sugar (monosaccharide, disaccharide, etc.) as possible, but less than 5 g (low sugar, fine sugar, sugar cut), less than 0.5 g (sugar-free) per 100 g or 100 ml of food. , Non-sugar, sugar-less, sugar-zero) sugars. Moreover, as sugars, palatinose, trehalose, sugar alcohol, etc. with little increase in blood glucose level after ingestion may be used.
In the present invention, the container for storing food is preferably an easily openable container, and preferably has self-supporting properties.
The packaged food of the present invention is suitable for nutritional supplementation, particularly for nutritional supplementation during sports, but is preferably used for improving blood glucose level. Moreover, when the alcoholic beverage of the present invention, for example, a 350 ml can of beer is drunk before meals, it is suitable for improving the blood sugar level increase due to the ingested food and alcohol.

  Regarding alcoholic beverages of the present invention, particularly beer-taste fermented beverages (beer, sparkling liquor), in order to reduce calorie, products containing isoleucine are particularly included in products that pay attention to foam quality and flavor deterioration. preferable. More specifically, without using malt or barley, a pre-fermentation solution is produced using a carbon source-containing syrup, hop, pigment, flavor, raw material that improves fermentability and water as raw materials, Happoshu (beer-like sparkling alcoholic beverage) can be produced by fermentation using yeast. Under the present circumstances, the indigestible dextrin pine fiber C (made by Matsutani Chemical) can be used as a raw material which reduces saccharide | sugar. More specifically, pea protein (pea protein, manufactured by Organo Rhodia Food), caramel pigment (Kokuyo Caramel, manufactured by Ikeda Saccharification Co., Ltd.), hop pellets are added with hot water, and further syrup is added to dissolve, 60 to 90 Boil for a minute. Then, hop cake etc. are removed in a sedimentation tank, it cools with a plate cooler, and 10 degreeC pre-fermentation liquid is obtained. To this pre-fermentation solution, pine fiber C of indigestible dextrin is added, and brewer's yeast is added thereto and fermented at 6-12 ° C for 5 days. Then, store at -1 ° C. The fermentation broth can be filtered using diatomaceous earth to remove yeast, and isoleucine can be added to produce an isoleucine-containing sparkling liquor. This isoleucine-containing sparkling liquor preferably contains indigestible dextrin and contains as little saccharide (monosaccharide, disaccharide, etc.) as possible, or contains saccharide in the above amount.

The food of the present invention may be taken by a healthy person who is not worried about health for daily blood sugar level management, but is particularly useful when there is anxiety about blood sugar (value). When there is anxiety about blood sugar (value), it shows a blood sugar level (transition) that is different from that of a healthy person, and there is a possibility that it may shift to a disease such as diabetes in the future. That is, when the postprandial blood glucose level or fasting blood glucose level tends to be slightly higher than that of a healthy person but is not diagnosed as a disease such as diabetes (for example, fasting blood glucose level of 100 mg / dl or more, more preferably 130 to 140 mg / dl ) And so-called borderline diabetes. In such a case, it is better to take it from the time when the blood sugar level starts to be worrisome. Ingestion can be expected to suppress a rapid increase in blood glucose level, improve fasting blood glucose level, and promote recovery of postprandial blood glucose level. In particular, continuous ingestion can be expected to improve fasting blood glucose levels and promote recovery of postprandial blood glucose levels.
More specifically, the food of the present invention can be used in the following manner.

When a fasting blood glucose level is diagnosed as being high in a medical examination or the like, a glucose tolerance test is performed, and it is determined whether diabetes treatment is necessary from the blood glucose level transition and the state of insulin secretion. In middle-aged and elderly people, although diabetes is not diagnosed, guidance may be given if medication or treatment is required if pancreatic function decreases due to aging in the future. These middle-aged and elderly people need to improve their blood sugar on a daily basis, and try to improve their lives by paying attention to avoiding overeating, suppressing weight gain, and exercising to maintain muscles that decrease with age. .
INDUSTRIAL APPLICABILITY The present invention can provide a food useful for improving daily blood sugar in middle-aged and elderly people who have particularly fasting blood glucose of 130 to 140 mg / dl and no particular abnormality in liver function.
By continuously ingesting the food of the present invention, it is possible to improve a state in which the blood sugar level is maintained at a blood glucose level of 150 mg / dL or more for one hour or longer in a glucose tolerance test and the blood glucose lowering is slow.
At this time, exercise after meals also has an effect of improving blood glucose, but the intake of the food of the present invention can further enhance the improvement effect and prevent the transition to diabetes.

EXAMPLES Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited only to the following examples.
Example 1
The effect of improving blood glucose level by L-isoleucine was examined in 4 healthy adult volunteers as subjects. Under fasting, 1 g or 2 g of isoleucine was dissolved in a glass of white hot water (about 150 cc, free of sugar) and stored in an easily openable and self-supporting container having an internal volume of about 150 cc. All the solutions in this container were taken at a time 10 minutes before the cooked rice load. Two rice balls (77.4g of carbohydrates, 372kcal) are ingested as cooked rice, blood is collected immediately before eating (0 minutes), 30 minutes, 1 hour, 2 hours, 3 hours after eating, and a simple blood glucose measurement device (ACCU-CHEK, Roche ) Was used to measure the blood glucose level. The control was intake of only white water containing no isoleucine contained in an easily openable container having an internal volume of about 150 cc. Moreover, you may use what melt | dissolved isoleucine in the tea type | system | group drink and the sports type | system | group drink other than white hot water.

FIG. 1 shows changes in blood glucose level for each subject in Example 1. The blood glucose level was obtained by subtracting the blood glucose level immediately before meal (0 minute value) from the blood glucose level at each measurement point. In the figure, ◯: control (white water only), ▲: isoleucine 1 g, ■: isoleucine 2 g.
As shown in FIG. 1, the increase in blood glucose level due to the load of cooked rice was suppressed in 2 cases among 4 subjects by taking 1 g of isoleucine, and the increase in blood glucose level was suppressed in all cases when the dose was further increased to 2 g.
FIG. 2 shows changes in blood glucose level (average value) of each group in Example 1. As the blood glucose level, an average value obtained by subtracting the blood glucose level immediately before meal (0 minute value) from the blood glucose level at each measurement point was displayed (average value ± standard deviation, n = 4). In the figure, ◯: control (white water only), ▲: isoleucine 1 g, ■: isoleucine 2 g.
As shown in FIG. 2, the dose-dependent improvement effect by isoleucine was recognized from the analysis of the average value of 4 cases.
FIG. 3 shows the blood sugar elevation area (AUC0-3h) of each group in Example 1. The blood glucose elevation area (AUC0-3h) indicates the area of elevation from the blood glucose level immediately before meal (0 minute value) from 0 minutes immediately before meal to 3 hours after meal (mean ± standard deviation, n = 4). In the figure, □: control (only white water), ■: isoleucine 1 g, ■: isoleucine 2 g, *: Dunnett's multiple comparison test P <0.05.
As shown in FIG. 3, in the comparison of the blood sugar elevation area (ΔAUC0-3h) from 0 minutes immediately before meal to 3 hours after meal, a significant decrease in blood sugar elevation area was observed in the isoleucine 2g intake group.

Example 2
Table 1 shows the background of the subjects who were evaluated as requiring a glucose tolerance test in the health examination.
Table 1

GOT, GPT and γ-GTP, which show liver function, have no abnormalities and no liver damage, but blood glucose level improvement effect by continuous ingestion of L-isoleucine in subjects who have been in a state of high fasting blood glucose for 2 years It was investigated.
After the subject was ingested 3 g of isoleucine for 29 days just before breakfast and just before dinner, the fasting blood glucose level and the glucose tolerance test were examined for up to 3 hours after ingestion of 75 g of sugar (sugar tolerance test a). In addition, a glucose tolerance test was performed after a period of not taking isoleucine for 7 days (sugar tolerance test b) and compared with the case of continuous intake. Furthermore, the glucose tolerance test similar to that after no intake of isoleucine was performed 12 days after resuming the intake of isoleucine, and the effect of improving blood glucose was examined (sugar tolerance test c).

Glucose tolerance test a

Glucose tolerance test b

Glucose tolerance test c

FIG. 4 shows changes in blood glucose level for each glucose tolerance test a to c in Example 2. In the figure, ○: glucose tolerance test a, ▲: glucose tolerance test b, ■: glucose tolerance test c.
FIG. 5 shows the blood sugar elevation area (AUC0-3h) in each test (sugar tolerance test a to c) in Example 2. The blood glucose elevation area (AUC0-3h) indicates the area from the blood glucose level immediately before meal (0 minute value) from 0 minutes immediately before meal to 3 hours after meal.
FIG. 6 shows changes in fasting blood glucose levels in Example 2. In the figure, 1 year before the start: 20061016 measured value in Table 1, 1 day before the start: 20071016 measured value in Table 1, 30 days after the start: immediately before the glucose tolerance test a, 8 days after the interruption: immediately before the glucose tolerance test b, 13 days after resumption: The value immediately before the glucose tolerance test c is shown.

Example 3
1. Preparation of beverage I (L-isoleucine, indigestible dextrin blended) After 3 g of indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd., trade name “Pine Fiber C”) and 2.5 g of L-isoleucine were uniformly mixed, The mixture was placed in 100 mL of tap water in a glass container while stirring and heated to about 80 ° C. with a microwave oven. After heating, the mixture was further stirred to dissolve both to obtain a colorless and transparent liquid beverage.
After allowing to cool at room temperature, the taste of the adjustment liquid was confirmed, and further kept in a refrigerator for 12 hours to confirm the presence or absence of precipitates.
Compared with the case where only L-isoleucine was dissolved in tap water, the bitter taste of L-isoleucine was reduced.

2. Preparation of Beverage II (L-isoleucine, indigestible dextrin, coffee blended) 1 g of instant coffee (trade name: The Blend 117, manufactured by UCC Ueshima Coffee Co., Ltd.) was prepared by re-preparing the beverage and allowing it to cool at room temperature. To prepare a coffee-based beverage. This preparation was easier to ingest than the preparation prepared with tap water.
3. Preparation of Beverage III (L-isoleucine, blended with coffee) 3 g of instant coffee was blended with the same beverage I except that no indigestible dextrin was blended to prepare a coffee beverage (sugar-free). It was a coffee drink with an excellent feeling of taking.
Thus, the L-isoleucine containing drink which mix | blended indigestible dextrin and / or coffee was a drink excellent in the ingestion feeling.

FIG. 1 is a diagram showing a blood glucose level transition for each subject in Example 1. FIG. 2 is a graph showing changes in blood glucose level (average value) of each group in Example 1. FIG. 3 shows blood glucose elevation area (AUC0-3h) in each group in Example 1. The blood glucose elevation area (AUC0-3h) indicates the area from the blood glucose level immediately before meal (0 minute value) from 0 minutes immediately before meal to 3 hours after meal. FIG. 4 is a graph showing changes in blood glucose level in each test (ac) in Example 2. FIG. 5 shows the blood sugar elevation area (AUC0-3h) in Example 2. The blood glucose elevation area (AUC0-3h) indicates the area from the blood glucose level immediately before meal (0 minute value) from 0 minutes immediately before meal to 3 hours after meal. 6 is a graph showing changes in fasting blood glucose levels in Example 2. FIG.

Claims (11)

A coffee-based beverage containing isoleucine and indigestible dextrin does not contain sugars other than indigestible dextrin, once packaged coffee beverage for at least 1g ingest isoleucine at doses. The containered beverage according to claim 1 for taking at least 2g of isoleucine in a single dose. The beverage in a container according to claim 1 or 2, for taking up to 15g of isoleucine in a single dose. The container-containing beverage according to claim 1 for ingesting 1 to 3 g of isoleucine in a single dose. Furthermore, the container-containing drink of any one of Claims 1-4 containing a leucine and / or valine. The container-containing beverage according to claim 1, containing 3.5 to 10.5g of isoleucine per 350ml. The container is an easily openable container, The container-containing beverage according to any one of claims 1 to 6 . The beverage in a container according to any one of claims 1 to 7 , which is used for improving blood glucose level. The beverage in a container according to claim 8 , wherein the blood glucose level improvement is for fasting blood glucose level improvement. The container-containing beverage according to claim 9 , wherein the blood glucose level improving agent is for promoting postprandial blood glucose level recovery. 9. The beverage in a container according to claim 8 , wherein the blood glucose level improving drug is for fasting blood glucose level of 100 mg / dl or more.

Images